Leptomeningeal Metastasis
…but unfortunately not uncommon in metastatic (Stage IV) melanoma. LMD is named after the structures of the brain, the leptomeninges. Together the…
Leptomeningeal Metastasis
…but unfortunately not uncommon in metastatic (Stage IV) melanoma. LMD is named after the structures of the brain, the leptomeninges. Together the…
Contact Us
Get in Touch Thank you for visiting AIM at Melanoma’s website. Mailing Address: AIM at Melanoma 5729 Lebanon Road, Suite 144-305…
How to Tell a Mole from Melanoma
…the ABCDEs of melanoma and the Ugly Duckling Rule. If you notice any of the following, consult your doctor or…
Types of Melanoma Treatment
Treatment for melanoma may include surgery, immunotherapy, targeted therapy, either alone or in combination, or radiation therapy. Your treatment…
Melanoma Support By State
Find Melanoma Support in Your Local Area Whether you’re a patient, family member, friend, loved one, or caregiver, there are…
Sunscreen
…of sunscreen was clearly demonstrated in a large Australian randomized trial published in 2010, which showed a 50% decreased melanoma…
Our Industry Partners
Discovering the Cure for Melanoma, Together Our goal is to align with corporate partners that share our commitment to finding…
Helpful Organizations
…AL 36830 Phone: (334) 748-2213 Website: www.eyeongracefoundation.org/ The Eye on Grace Foundation exists to help alleviate the financial burden of…
Connecticut
…Cedar Street New Haven, CT 06520 203-200-6622 yalecancercenter.org Deepak Narayan, MD, Clinical Program Leader, Melanoma Program Mario Sznol, MD, Disease…
Planned Giving
Your legacy can fund melanoma research. Leaving a gift to AIM as part of your estate is a wonderful way…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026